Stifel Nicolaus upgraded shares of Edwards Lifesciences (NYSE:EW – Free Report) from a hold rating to a buy rating in a report published on Thursday morning, Ratings reports. The firm currently has $90.

In this article we are going to estimate the intrinsic value of Edwards Lifesciences Corporation ( NYSE:EW) by taking the forecast future cash flows of the company and discounting them back to today's value. We will use the Discounted Cash Flow (DCF) model on this occasion. It may sound complicated, but actually it is quite simple!

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR,

Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.13 which represents a decrease of $-1.43 or -1.97% from the prior close of $72.56. The stock opened at $72.5 and touched a low of $71.

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also increased its price target on the company from $75.